Ecolab (ECL)
(Delayed Data from NYSE)
$244.57 USD
-1.16 (-0.47%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.55 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$244.57 USD
-1.16 (-0.47%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $244.55 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth B Momentum C VGM
Zacks News
Reasons to Retain Ecolab (ECL) Stock in Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on cost efficiency programs raises optimism about the stock.
Top Analyst Reports for Cisco Systems, NextEra Energy & Moody's
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), NextEra Energy, Inc. (NEE) and Moody's Corporation (MCO).
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
by Zacks Equity Research
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
Linde's (LIN) Q2 Earnings Top on Solid Americas Business Unit
by Zacks Equity Research
Higher pricing from the Americas segment backs Linde's (LIN) Q2 earnings beat.
Looking for a Growth Stock? 3 Reasons Why Ecolab (ECL) is a Solid Choice
by Zacks Equity Research
Ecolab (ECL) possesses solid growth attributes, which could help it handily outperform the market.
Ecolab (ECL) Sells Surgical Solutions Business to Medline
by Zacks Equity Research
Ecolab's (ECL) deal to sell its global surgical solutions business to Medline enables it to focus on infection prevention and instrument reprocessing while enhancing shareholders' returns.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Invesco Global Water ETF (PIO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PIO
Are Basic Materials Stocks Lagging Eldorado Gold (EGO) This Year?
by Zacks Equity Research
Here is how Eldorado Gold Corporation (EGO) and Ecolab (ECL) have performed compared to their sector so far this year.
How to Find Strong Basic Materials Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Ecolab (ECL) Q2 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its second-quarter sales amid business challenges.
Ecolab (ECL) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Ecolab (ECL) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ecolab (ECL) Q2 Earnings Beat Estimates
by Zacks Equity Research
Ecolab (ECL) delivered earnings and revenue surprises of 1.20% and 1.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can These 3 Medical Device Stocks Hit Earnings This Season?
by Zacks Equity Research
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how ECL, SYK and FMS are placed ahead of their earnings releases.
Countdown to Ecolab (ECL) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Ecolab (ECL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Factors Setting the Tone for Ecolab's (ECL) Q2 Earnings
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.
What's in Store for Materials ETFs in Q2 Earnings?
by Sweta Killa
Going into the Q2 earnings season, earnings releases from the sector giants will determine the movement of these funds.
Suzano (SUZ) to Buy 2 Mills From Pactiv Evergreen for $110M
by Zacks Equity Research
Suzano (SUZ) signs an agreement with Pactiv Evergreen to acquire two of its US industrial facilities.
Is Invesco Water Resources ETF (PHO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PHO
Should You Invest in the Invesco Water Resources ETF (PHO)?
by Zacks Equity Research
Sector ETF report for PHO
Barrick (GOLD) Announces Strategic Plans for Loulo-Gounkoto
by Zacks Equity Research
Barrick (GOLD) emphasizes the importance of sustaining the Loulo-Gounkoto gold mining complex, with a significant economic contribution to Mali.
3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance
by Zacks Equity Research
Orthofix Medical (OFIX) announces the FDA clearance and first U.S. implant of the Fitbone Transport and Lengthening System, used to treat large bone defects in the femur and tibia.
Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit
by Zacks Equity Research
Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.
Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028
by Zacks Equity Research
The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.